| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
TC HSD 21 is a potent 17β-hydroxysteroid dehydrogenase type 3 (17β-HSD3) inhibitor with an IC50 of 14 nM. IC50 values are 6 and 40 nM at human and mouse 17β-HSD3, respectively. It displays no activity at 17β-HSD1. 17β-HSD3 is a crucial enzyme in the final step of testosterone synthesis in the testes, catalyzing the conversion of androstenedione to testosterone. The compound also shows excellent selectivity over 17β-HSD isoenzymes and nuclear receptors.
|
|---|---|
| ln Vitro |
In vitro, TC HSD 21 demonstrates potent inhibition of 17β-HSD3 enzyme activity. It is a cell-permeable compound, making it suitable for cellular assays. It shows excellent selectivity over other 17β-HSD isoenzymes and nuclear receptors. The compound is used to dissect androgen biosynthesis and 17β-HSD3-dependent pathways in cell-based systems.
|
| ln Vivo |
In vivo, TC HSD 21 is used to study the role of testicular androgen production in disease models. By inhibiting 17β-HSD3, it blocks testosterone synthesis in the testes. This makes it a valuable tool for studying androgen-dependent diseases and endocrine regulation. It regulates glucocorticoid metabolism by blocking local cortisol regeneration, thereby affecting glucose metabolism and inflammatory responses.
|
| Enzyme Assay |
For non-cellular enzyme/receptor binding assays, the compound's inhibition of 17β-HSD3 can be assessed using enzyme activity assays with purified 17β-HSD3 protein. The conversion of androstenedione to testosterone is measured in the presence of varying concentrations of TC HSD 21. IC50 values are determined. Selectivity over other 17β-HSD isoenzymes and nuclear receptors can be assessed using similar enzyme activity assays or radioligand binding assays.
|
| Cell Assay |
For in vitro cell-based assays, cells expressing 17β-HSD3 are cultured and treated with TC HSD 21. Testosterone production is measured to assess enzyme inhibition. Cell permeability allows for intracellular target engagement. The compound can be used to study the effects of 17β-HSD3 inhibition on androgen biosynthesis and downstream signaling pathways in various cell types.
|
| Animal Protocol |
For in vivo animal studies, TC HSD 21 is administered to animal models to study steroid metabolism and endocrine regulation. It can be used to investigate the role of testicular androgen production in disease models. By blocking local cortisol regeneration, it affects glucose metabolism and inflammatory responses. Dosing regimens and routes of administration depend on the specific experimental model.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties include solubility in DMSO (10 mM * 1 mL in DMSO ready for reconstitution). The powder is stable at -20°C for 3 years and at 4°C for 2 years. In solvent, it is stable at -80°C for 6 months and at -20°C for 1 month. The appearance is a solid, light yellow to yellow. The molecular weight is 422.32.
|
| Toxicity/Toxicokinetics |
In preclinical studies, TC HSD 21 has shown good selectivity and potency. No significant toxicity has been reported. It is a controlled substance and not for sale in some territories. The compound is for research use only and not for human use.
|
| Additional Infomation |
TC HSD 21 is a potent and highly selective inhibitor of 17β-hydroxysteroid dehydrogenase type 3 (IC50 = 14 nM). It is a valuable tool for dissecting androgen biosynthesis and 17β-HSD3-dependent pathways. It is used in studies of steroid metabolism, endocrine regulation, and the role of testicular androgen production in disease models. It shows excellent selectivity over 17β-HSD isoenzymes and nuclear receptors.
|
| Molecular Formula |
C17H12BRNO3S2
|
|---|---|
| Molecular Weight |
422.316081047058
|
| Exact Mass |
420.944
|
| CAS # |
330203-01-5
|
| PubChem CID |
1774851
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
4.634
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
24
|
| Complexity |
534
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
BrC1=C(C=CC(=C1)/C=C1/C(N(C(=S)S/1)C1C=CC(=CC=1)OC)=O)O
|
| InChi Key |
HEFKAUYVLSGPGC-DHDCSXOGSA-N
|
| InChi Code |
InChI=1S/C17H12BrNO3S2/c1-22-12-5-3-11(4-6-12)19-16(21)15(24-17(19)23)9-10-2-7-14(20)13(18)8-10/h2-9,20H,1H3/b15-9-
|
| Chemical Name |
(5Z)-5-[(3-bromo-4-hydroxyphenyl)methylidene]-3-(4-methoxyphenyl)-2-sulfanylidene-1,3-thiazolidin-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 250 mg/mL (~591.97 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3679 mL | 11.8394 mL | 23.6787 mL | |
| 5 mM | 0.4736 mL | 2.3679 mL | 4.7357 mL | |
| 10 mM | 0.2368 mL | 1.1839 mL | 2.3679 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
